首页|The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
Baicalein is the main active compound of Scutellaria baicalensis Georgi, a medicinal herb with multiple pharmacological activities, including the broad anti-virus effects. In this paper, the preclinical study of baicalein on the treatment of COVID-19 was performed. Results showed that baicalein inhibited cell damage induced by SARS-CoV-2 and improved the morphology of Vero E6 cells at a concentration of 0.1 mu M and above. The effective concentration could be reached after oral administration of 200 mg/kg crystal form beta of baicalein in rats. Furthermore, baicalein significantly inhibited the body weight loss, the replication of the virus, and relieved the lesions of lung tissue in hACE2 transgenic mice infected with SARS-CoV-2. In LPS-induced acute lung injury of mice, baicalein improved the respiratory function, inhibited inflammatory cell infiltration in the lung, and decreased the levels of IL-1 beta and TNF-alpha in serum. In conclusion, oral administration of crystal form beta of baicalein could reach its effective concentration against SARS-CoV-2. Baicalein could inhibit SARS-CoV-2-induced injury both in vitro and in vivo. Therefore, baicalein might be a promising therapeutic drug for the treatment of COVID-19.
NSTL
Elsevier
